Details of the Drug

General Information of Drug (ID: DMOX1CU)

Drug Name

NCX-4016

Synonyms

Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Phase 2	[1]
Claudication	FA11	Discontinued in Phase 2	[2]
Nephropathy	GC2Z	Discontinued in Phase 2	[2]
Type-2 diabetes	5A11	Discontinued in Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

331.28

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C16H13NO7
IUPAC Name: [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate
Canonical SMILES: CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]
InChI: InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3
InChIKey: IOJUJUOXKXMJNF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 119032
ChEBI ID: CHEBI:125482
CAS Number: 175033-36-0
DrugBank ID: DB12445
TTD ID: D05OQX

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[3]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[4]
Cyclic AMP-dependent transcription factor ATF-2 (ATF2)	OTNIZPEA	ATF2_HUMAN	Post-Translational Modifications	[5]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[5]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[5]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Post-Translational Modifications	[5]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Gene/Protein Processing	[3]
Transcription factor 4 (TCF4)	OTB9ASTK	ITF2_HUMAN	Gene/Protein Processing	[6]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Post-Translational Modifications	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7.
2	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
3	Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
4	NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J Physiol Pharmacol. 2006 Dec;57 Suppl 12:15-24.
5	Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther. 2006 Jan;316(1):25-34. doi: 10.1124/jpet.105.091363. Epub 2005 Sep 16.
6	Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 2009 Nov 15;78(10):1298-304.